[HTML][HTML] PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in …
…, D Conklin, O Kalous, DJ Cohen, AJ Desai… - Breast Cancer …, 2009 - Springer
Introduction Alterations in cell cycle regulators have been implicated in human malignancies
including breast cancer. PD 0332991 is an orally active, highly selective inhibitor of the …
including breast cancer. PD 0332991 is an orally active, highly selective inhibitor of the …
Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in …
Purpose: HER2 amplification occurs in 18% to 27% of gastric and gastroesophageal junction
cancers. Lapatinib, a potent ATP-competitive inhibitor simultaneously inhibits both EGFR …
cancers. Lapatinib, a potent ATP-competitive inhibitor simultaneously inhibits both EGFR …
PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar …
JE Logan, N Mostofizadeh, AJ Desai… - Anticancer …, 2013 - ar.iiarjournals.org
Background: PD-0332991 is an inhibitor of cyclin-dependent kinases (CDK) 4 and 6, and
was evaluated to determine its anti-proliferative effects in 25 renal cell carcinoma (RCC) cell …
was evaluated to determine its anti-proliferative effects in 25 renal cell carcinoma (RCC) cell …
Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib
O Kalous, D Conklin, AJ Desai, NA O'Brien… - Molecular cancer …, 2012 - AACR
The human EGF (HER) family of receptors has been pursued as therapeutic targets in breast
cancer and other malignancies. Trastuzumab and lapatinib are standard treatments for …
cancer and other malignancies. Trastuzumab and lapatinib are standard treatments for …
Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer
ZA Wainberg, A Anghel, AM Rogers, AJ Desai… - Molecular cancer …, 2013 - AACR
HSP90 enables the activation of many client proteins of which the most clinically validated
is HER2. NVP-AUY922, a potent HSP90 inhibitor, is currently in phase II clinical trials. To …
is HER2. NVP-AUY922, a potent HSP90 inhibitor, is currently in phase II clinical trials. To …
The HSP90 inhibitor NVP-AUY922 potently inhibits non–small cell lung cancer growth
…, J Dering, S Pitts, N Kamranpour, AJ Desai… - Molecular cancer …, 2013 - AACR
Heat shock protein 90 (HSP90) is involved in protein folding and functions as a chaperone
for numerous client proteins, many of which are important in non–small cell lung cancer (…
for numerous client proteins, many of which are important in non–small cell lung cancer (…
[HTML][HTML] Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non–small-cell lung cancer
…, DC Márquez-Garbán, AJ Desai, J Dering… - Journal of Thoracic …, 2013 - Elsevier
Introduction Estrogen receptor (ER) signaling and its interaction with epidermal growth
factor receptor (EGFR) is a potential therapeutic target in non–small-cell lung cancer (NSCLC). …
factor receptor (EGFR) is a potential therapeutic target in non–small-cell lung cancer (NSCLC). …
In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response
…, O Kalous, D Conklin, AJ Desai, J Dering… - Breast cancer research …, 2015 - Springer
Everolimus (RAD001, Afinitor ® ) is an oral, selective mTOR inhibitor recently approved by
the US-FDA in combination with exemestane for treatment of hormone receptor positive …
the US-FDA in combination with exemestane for treatment of hormone receptor positive …
AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53
…, D Conklin, AJ Desai, J Dering, J Goldstein… - Breast cancer research …, 2013 - Springer
Aurora kinases play important roles in cell division and are frequently overexpressed in human
cancer. AMG 900 is a novel pan-Aurora kinase inhibitor currently being tested in Phase I …
cancer. AMG 900 is a novel pan-Aurora kinase inhibitor currently being tested in Phase I …
Design of decision support interventions for medication prescribing
OBJECTIVE: Describe optimal design attributes of clinical decision support (CDS)
interventions for medication prescribing, emphasizing perceptual, cognitive and functional …
interventions for medication prescribing, emphasizing perceptual, cognitive and functional …